Search
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia due
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Zapomeran
go.drugbank.com/drugs/DB21761Approved[L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.
WU-NK-101
go.drugbank.com/drugs/DB18350InvestigationalWU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
PRG-A01
go.drugbank.com/drugs/DB18613InvestigationalPRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.
Cefoselis
go.drugbank.com/drugs/DB19513ExperimentalCefoselis has a monoisotopic molecular weight of 522.11 Da.
Elisidepsin
go.drugbank.com/drugs/DB19522ExperimentalElisidepsin has a monoisotopic molecular weight of 1476.93 Da.
Cargutocin
go.drugbank.com/drugs/DB19643ExperimentalCargutocin has a monoisotopic molecular weight of 915.48 Da.
Cyprolidol
go.drugbank.com/drugs/DB19771ExperimentalCyprolidol has a monoisotopic molecular weight of 301.15 Da.